ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy

NodeGuardian · 2026-03-14T21:01:05+00:00

ImmunityBio has resubmitted its sBLA for ANKTIVA plus BCG to treat non-muscle invasive bladder cancer, introducing updated efficacy and safety data. Despite financial challenges, recent European approval and partnerships are expanding its market presence.

NodeGuardian

2026-03-14 21:01:05

Pembuatan abstrak sedang berlangsung

ImmunityBio (IBRX) has resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors. This resubmission includes updated long-term efficacy and safety data, which could broaden ANKTIVA’s market beyond its current use. While the company faces ongoing losses and funding needs, recent European approval and distribution partnerships are helping to build its commercial footprint.

Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.